European Psychiatry - Volume 33 - March 2016

677 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S673
the modification of the oral regimen. PANSS and CGI. Metabolic
profile: weight, glycaemia, and total cholesterol, LDL and HDL,
triglycerides. Cost at the beginning and after 6 months.
Results Mean age: 44.50 years, 54% women. Marital status: 54%
single, 27% married, 27% divorced. Mean time from diagnosis:
11 years. Toxic consumption: 27% active, 18% ex-drug users. Three
patients were readmitted after introducing LAA, 2 of them were
for abandoning medication (including LAA). PANSS at 6 months
showed statistically significant differences in negative subscale
(3 points). No statistical differences in positive and general psy-
chopathology subscales. No metabolic side effect was found.
Average saving per patient 37.05 euros per month
Conclusion This study signalizes that LAA is an effective treat-
ment. Clinically, it has been shown that our patients improve
adherence and prevent relapse. Moreover, nometabolic side effects
were found. Besides, LAA is also efficient and we would save 407,55
euros per month.
Fig. 1
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1014
Twenty-four months experience of
paliperidone long-acting injection in a
Spanish psychiatric service: A mirror
image analysis
C. Gómez Sánchez-Lafuente ∗, R. Reina Gonzalez ,
F. Moreno De Lara , A. De Severac Cano , E. Mateos Carrasco ,
A. González Moreno
1 Hospital Universitario Virgen de la Victoria, Psychiatry, Málaga,
Spain
2 Hospital Regional Universitario, General Practitioner, Málaga, Spain
∗ Corresponding author.
Introduction Lack of adherence is a common cause of relapse in
schizophrenia. Long-acting antipsychotics have shown in recent
studies that they improve compliance. However, some randomised
controlled trials showed no difference in relapse rates between oral
medication and long-acting injections.
Objective To report the use of paliperidone palmitate in an Acute
Psychiatrist Unit in Spain.
Method Retrospective observational study of 42 patients pre-
scribed paliperidone palmitate (PLAI) during an admission at Acute
Psychiatric unit in Málaga. In the mirror image analysis, the main
outcome measure was the total number of days of psychiatric
inpatient care twelve months before and after patients started
Paliperidone palmitate.
Results Most common reason for starting paliperidone palmi-
tate was lack of adherence to oral medication (54%) followed
by lack of efficacy on previous medication (31%). Olanzapine
(47%) and risperidone (41%) were most commonly antipsychotics
prescribed before PLAI. Thirty-four patients continued PLAI over
twelve months (80%). Poor compliance was the most common
reason of withdrawal. Three patients had a movement disorder
adverse effect. Only one was lost because adverse effects. Total
admissions and inpatients days were significantly reduced from
the previous treatment to PLAI-treatment period
Conclusion PLAI was associated with a reduction in total inpa-
tient days. The financial saving from reduced admissions stays
exceeded the acquisition and administration cost of PLAI. Improved
compliance because of PLAI is themost plausible explanation of this
result
Table 1
Previous treatment period PLAI period
Total Admissions 81 45
Inpatient stays in days 943 516
Mean reduction in inpatient stays 10 days
Financial saving (euro/patient/year) 2905
Fig. 1
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.